Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway

Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide

(2014) Xiuming Song et al.   Pharmacological Reports

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

(2013) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors

(2013) Sylwester Glowacki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

(2013) Litao Zhu et al.   TOXICOLOGY LETTERS

Bone Marrow Microenvironment in Multiple Myeloma Progression

(2012) S. Manier et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrinβ1 and its related pathway

(2012) Binbin Zhu et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

(2011) E Traer et al.   LEUKEMIA

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML

(2011) Rajesh R. Nair et al.   LEUKEMIA RESEARCH

Oroxylin a reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-κB signaling pathway

(2011) Hui-Ying Yang et al.   MOLECULAR CARCINOGENESIS

Deactivation of Signal Transducer and Activator of Transcription 3 Reverses Chemotherapeutics Resistance of Leukemia Cells via Down-Regulating P-gp

(2011) Xulong Zhang et al.   PLoS One

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

(2010) A Samanta et al.   LEUKEMIA

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

(2010) D Bixby et al.   LEUKEMIA

Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice

(2009) Li Zhao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Contribution of BCR–ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells

(2009) Takeru Nambu et al.   CANCER SCIENCE

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

(2009) Ying Gao et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Stat3 Expression and Its Correlation with Proliferation and Apoptosis/Autophagy in Gliomas

(2009) Valentina Caldera et al.   Journal of Oncology

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

(2008) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

(2008) Nadine N. Bewry et al.   MOLECULAR CANCER THERAPEUTICS

Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond

(2008) J. V. Melo et al.   Hematology-American Society of Hematology Education Program